About PlasmaGen BioSciences
PlasmaGen BioSciences is a company based in Bengaluru (India) founded in 2010 by Vinod Nahar. PlasmaGen BioSciences has raised $84.55 million across 5 funding rounds from investors including Eight Roads Ventures, RSM Pharma and Trigenesis Lifesciences. The company has 262 employees as of April 05, 2024. PlasmaGen BioSciences operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Bengaluru, India
- Employees 262 as on 05 Apr, 2024
- Founders Vinod Nahar
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Plasmagen Biosciences Private Limited
- Date of Incorporation 07 Sep, 2010
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$13.21 M (USD)4.98as on Mar 31, 2023
-
Net Profit
-$1.41 M (USD)-298.3as on Mar 31, 2023
-
EBITDA
-$1.34 M (USD)-275.76as on Mar 31, 2023
-
Total Equity Funding
$84.55 M (USD)
in 5 rounds
-
Latest Funding Round
$16.73 M (USD), Series D
Dec 22, 2025
-
Investors
Eight Roads Ventures
& 15 more
-
Employee Count
262
as on Apr 05, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of PlasmaGen BioSciences
PlasmaGen BioSciences has successfully raised a total of $84.55M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $16.73 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PlasmaGen BioSciences
PlasmaGen BioSciences has secured backing from 16 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Eight Roads Ventures, RSM Pharma and Trigenesis Lifesciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investment and global platform support for startups.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Artian is an investment management firm providing portfolio and asset management services to clients.
|
Locked | Locked | Locked |
Investor details for PlasmaGen BioSciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PlasmaGen BioSciences
Investment portfolio details for PlasmaGen BioSciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PlasmaGen BioSciences
Detailed financials for PlasmaGen BioSciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Plasmagen Biosciences Comparisons
Peer comparison for PlasmaGen BioSciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PlasmaGen BioSciences
PlasmaGen BioSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Detailed competitors of PlasmaGen BioSciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Plasmagen Biosciences
Complete news archive for PlasmaGen BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PlasmaGen BioSciences
PlasmaGen BioSciences was founded in 2010 and raised its 1st funding round 7 years after it was founded.
PlasmaGen BioSciences is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
PlasmaGen BioSciences is a funded company, having raised a total of $84.55M across 5 funding rounds to date.
As of Apr 05, 2024, the latest employee count at PlasmaGen BioSciences is 262.
Annual revenue of PlasmaGen BioSciences is $13.21M as on Mar 31, 2023.
PlasmaGen BioSciences was established in 2010 in Bengaluru, India, within the biopharmaceutical sector. Focus is placed on products derived from blood plasma, such as albumin, immunoglobulins, coagulation factors, and specialty therapies. Operations aim to enhance accessibility of these treatments across India and emerging markets, supporting care in plasma protein and specialty therapy areas.
PlasmaGen BioSciences's top competitors include Merck, Roivant Sciences and AbbVie.
PlasmaGen BioSciences has 16 investors. Key investors include Eight Roads Ventures, RSM Pharma, Trigenesis Lifesciences, Kemwell, and F-Prime Capital.
The valuation of PlasmaGen BioSciences is $48.28M as of Mar 2023.